Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon-β injections: A case report
| Autor: | Yoshie Teshima, Daiki Matsubara, Yui Takahara, Michihiro Hide, Takanobu Kan, Akio Tanaka, Shunsuke Takahagi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty education.field_of_study Oncogene local injection business.industry Melanoma Population malignant melanoma Cancer Articles medicine.disease Molecular medicine Refractory quality of life Apoptosis interferon-β Internal medicine medicine Adjuvant therapy in-transit metastasis business education |
| Zdroj: | Molecular and Clinical Oncology |
| ISSN: | 2049-9469 2049-9450 |
| Popis: | In-transit metastases (ITMs) in patients with malignant melanoma (MM) are associated with poor prognosis and a worse disease burden compared with MM without ITMs. A substantial population of patients with ITMs show no or only poor responses to newly developed therapies, such as immune checkpoint inhibitors or molecular-targeted agents. It is difficult to control the exudate and bleeding from ITMs when these medications are ineffective. In Japan, local injection of interferon-β (IFN-β) has been licensed for years as adjuvant therapy for MM. However, the evidence for IFN-β effectiveness for ITMs remains low. The present report describes a case of MM with multiple ITMs that did not respond to a programmed cell death-1 inhibitor and local injections of IFN-β at 3 million IU/day for 5 days/4 weeks but remitted upon increasing the amount of IFN-β injections to 10 consecutive days/4 weeks. Local IFN-β therapy could be an option for improving the quality of life of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|